1,289
Views
11
CrossRef citations to date
0
Altmetric
Rheumatology

Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study

, , , , , , & show all
Pages 657-666 | Received 29 Sep 2016, Accepted 21 Dec 2016, Published online: 25 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ana Teresa Melo, Raquel Campanilho-Marques & João Eurico Fonseca. (2021) Golimumab (anti-TNF monoclonal antibody): where we stand today. Human Vaccines & Immunotherapeutics 17:6, pages 1586-1598.
Read now

Articles from other publishers (9)

John Tesser, Iris Lin, Natalie J. Shiff, Soumya D. Chakravarty, Gabriela Schmajuk, Nevin Hammam & Sheetal Desai. (2022) Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry. Clinical Rheumatology 41:8, pages 2319-2327.
Crossref
Roy Fleischmann. (2021) Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis. Clinical Rheumatology 40:11, pages 4369-4372.
Crossref
Florenzo Iannone, Ennio G. Favalli, Roberto Caporali, Salvatore D’Angelo, Francesco Paolo Cantatore, Piercarlo Sarzi-Puttini, Rosario Foti, Fabrizio Conti, Antonio Carletto, Elisa Gremese, Alberto Cauli, Roberta Ramonda, Adalgisa Palermo, Oscar Epis, Marta Priora, Francesca Bergossi, Bruno Frediani, Fausto Salaffi, Giuseppe Lopalco, Fabio Cacciapaglia, Antonio Marchesoni, Martina Biggioggiero, Serena Bugatti, Silvia Balduzzi, Antonio Carriero, Addolorata Corrado, Sara Bongiovanni, Alessia Benenati, Francesca Miranda, Elena Fracassi, Daniela Perra, Gianfranco Ferraccioli & Giovanni Lapadula. (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88:1, pages 105062.
Crossref
Fatima Zamri & Teun J. de Vries. (2020) Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?. Frontiers in Immunology 11.
Crossref
Feliciana Real-Fernández, Francesca Pregnolato, Rolando Cimaz, Anna Maria Papini, Maria Orietta Borghi, Pier Luigi Meroni & Paolo Rovero. (2019) Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Analytical Biochemistry 566, pages 133-138.
Crossref
Natal’ya N. Chichasova. (2019) Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability. Current pediatrics 17:6, pages 449-457.
Crossref
E. V. IgolkinaN. V. Chichasova. (2018) The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics. Modern Rheumatology Journal 12:4, pages 23-31.
Crossref
Raphael J. Dehoratius, Lawrence H. Brent, Jeffrey R. Curtis, Lorie A Ellis & Kezhen L. Tang. (2018) Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. The Patient - Patient-Centered Outcomes Research 11:3, pages 361-369.
Crossref
Andrea Rubbert-Roth, Fabiola Atzeni, Ignazio Francesco Masala, Roberto Caporali, Carlomaurizio Montecucco & Piercarlo Sarzi-Puttini. (2018) TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. Autoimmunity Reviews 17:1, pages 24-28.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.